Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization
Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization
复制标题
DOI：
10.1038/nm0697-651
复制
发表时间：
1997-06-01
期刊：
影响因子：
82.9
通讯作者：
RobertGuroff, M
中科院分区：
文献类型：
--
作者：
Lubeck, MD;Natuk, R;RobertGuroff, M
在黑猩猩中评价了一种联合艾滋病疫苗方法，该方法包括用腺病毒-HIV-1（MN）gp 160重组体引发，然后用HIV-1（SF 2）gp 120加强。持久的保护，只需要三次免疫接种，实现了对低剂量的挑战与SF 2株的HIV-1和随后的高剂量SF 2挑战管理1年后，没有干预加强。值得注意的是，针对临床和实验室分离株的中和抗体应答在3只黑猩猩中产生，并持续至高剂量攻毒时。细胞毒性T淋巴细胞有助于行剂量保护的黑猩猩缺乏中和抗体的可能性建议。我们的研究结果验证了活载体引发/亚单位加强的方法，并应刺激在人类中评估这种组合疫苗的方法的兴趣。
A combination AIDS vaccine approach consisting of priming with adenovirus-HIV-1(MN)gp160 recombinants followed by boosting with HIV-1(SF2)gp120 was evaluated in chimpanzees. Long-lasting protection, requiring only three immunizations, was achieved against a low-dose challenge with the SF2 strain of HIV-1 and a subsequent high-dose SF2 challenge administered 1 year later without an intervening boost. Notably, neutralizing antibody responses against both clinical and laboratory isolates developed in three chimpanzees and persisted until the time of high-dose challenge. The possibility that cytotoxic T-lymphocytes contribute to row-dose protection of a chimpanzee lacking neutralizing antibodies is suggested. Our results validate the live vector priming/subunit booster approach and should stimulate interest in assessing this combination vaccine approach in humans.